Good news, Bensocatib Trials Continue for Bronchieactasis

@scoop @ rstel7272 @harrynsc
So, umm...let me point out this is a Stock Report, not a medical research paper. Can anyone point us to the underlying data - Phase 3 FDA research, double-blind study or retrospective evaluation?

Check out Linda Esposito's (@becleartoday) post of May 28 re Clinical Trials - she is a trustworthy source! Fingers crossed this is the real deal.

Hello @becleartoday - I merged your discussion with @harrynsc's discussion on the same topic - https://connect.mayoclinic.org/discussion/good-news-for-bronchiectasis/ so all of the members talking about this study could be in one place.

Like @sueinmn mentioned, the article linked in this discussion is a stock report. Have you been able to track down the study data link that you are referring to? I found one article, but it is from 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2021713.

What I'd want to know is how many participants were in the study and over what period of time.

The news just came out yesterday, so there aren’t medical journal articles on this top line data at this point in time.

I created this general discussion of ongoing active clinical trials at Colleen Young’s suggestion. But if you wish to move this to a previous discussion on brensocatib that makes sense as well.

You can read about the clinical trial by clicking on the link below. Also, if you Google “Aspen” and “brensocatib” you will find earlier articles from clinical and scientific journals.

Many of us have been waiting for this information ever since the trial completed its in enrollment in March 2023 of 1700 participants. Yesterday‘s news was tremendously significant for those of us with bronchiectasis who have frequent exacerbations. Even at the lower dose, there was approximately a 20% reduction in exacerbations. If approved by the FDA, this will be the first drug approved specifically for BE.

just made the daily mail: https://www.dailymail.co.uk/health/article-13483831/The-game-changing-new-treatment-rid-cough-just-wont-away.html?ns_mchannel=rss&ns_campaign=1490&ito=social-twitter_dailymailUK

Best news of the day!

The Arina-1 seems a lot more promising and benign in terms of side-effects. But still I am happy BE is finally getting attention from drug developers.

Yes!! BE is getting lots of attention. Brensocatib is considered to have a safe profile. On a recent call with industry and clinicians there was consensus that their drug would probably not need to be reviewed by the FDA adverse event committee.

Also, it’s meant for people who have frequent exacerbations.

Arina-1 Will perhaps be appropriate for the general bronchiectasis population.

Any of these available??